Dominari Holdings Inc (DOMH)
$1.88
Performance
- $1.85$1.91$1.88
1.6%
Downside
Day's Volatility :3.14%
Upside
1.57%
- $1.50$3.20$1.88
20.21%
Downside
52 Weeks Volatility :53.13%
Upside
41.25%
Returns
| Period | Dominari Holdings Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -8.54% | 0.0% |
6 Months | -13.99% | 0.0% |
1 Year | -27.88% | 0.0% |
3 Years | -42.92% | -20.8% |
Highlights
Market Capitalization | 12.0M |
Book Value | $6.78 |
Earnings Per Share (EPS) | -3.85 |
Wall Street Target Price | 16.0 |
Profit Margin | -231.55% |
Operating Margin TTM | -44.31% |
Return On Assets TTM | -15.19% |
Return On Equity TTM | -42.29% |
Revenue TTM | 9.5M |
Revenue Per Share TTM | 1.67 |
Quarterly Revenue Growth YOY | 8595.8% |
Gross Profit TTM | 0.0 |
EBITDA | -14.1M |
Diluted Eps TTM | -3.85 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 751.06%
Technicals Summary
Sell
Neutral
Buy
Dominari Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Dominari Holdings Inc | 18.67% | -13.99% | -27.88% | -42.92% | -42.92% |
 Regeneron Pharmaceuticals, Inc. | -2.2% | 20.15% | 39.88% | 76.57% | 303.42% |
 Novo Nordisk A/s | 1.56% | 3.09% | 46.83% | 167.63% | 453.76% |
 Alnylam Pharmaceuticals, Inc. | -1.11% | 79.95% | 47.56% | 39.47% | 212.93% |
 Vertex Pharmaceuticals Incorporated | 1.68% | 17.99% | 37.89% | 159.42% | 173.37% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Dominari Holdings Inc | NA | NA | NA | 0.0 | -0.42 | -0.15 | NA | 6.78 |
Regeneron Pharmaceuticals, Inc. | 30.86 | 30.86 | 1.59 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 46.01 | 46.01 | 2.08 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Dominari Holdings Inc | Buy | $12.0M | -42.92% | NA | -231.55% |
Regeneron Pharmaceuticals, Inc. | Buy | $128.4B | 303.42% | 30.86 | 32.04% |
Novo Nordisk A/s | Buy | $600.4B | 453.76% | 46.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.1B | 212.93% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $125.3B | 173.37% | 32.84 | -4.74% |
Insights on Dominari Holdings Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 43.9% return, outperforming this stock by 73.1%
Company Information
spherix presently offers a diversified commercialization platform for protected technologies. spherix is committed to advancing innovation by active participation in all areas of the patent market. spherix draws on portfolios of pioneering technology patents to partner with and support product innovation. through its recently announced acquisition of over a hundred patents from rockstar consortium inc and its previously announced acquisition of several hundred patents issued to harris corporation, spherix intends to expand its activities in wireless communications and telecommunication sectors including antenna technology, wi-fi, base station functionality, and cellular.
Organization | Dominari Holdings Inc |
Employees | 26 |
CEO | Mr. Anthony C. Hayes Esq. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$1.88
-2.34%
Keyarch Acquisition Corp
$1.88
-2.34%
Connexa Sports Technologies Inc
$1.88
-2.34%
Us Value Etf
$1.88
-2.34%
First Wave Biopharma Inc
$1.88
-2.34%
Global X Msci Next Emerging
$1.88
-2.34%
Fat Projects Acquisition Corp
$1.88
-2.34%
Capital Link Global Fintech
$1.88
-2.34%
Applied Uv Inc
$1.88
-2.34%